James Wade, senior analyst at Datamonitor Healthcare, talks about the pharmaceuticals industry which faces a "big patent cliff" at the moment, and discusses the outlook for next year.
LONDON, Dec 17- GlaxoSmithKline will stop paying doctors to promote its products at events and remove individual sales targets for its marketing staff in a first for the drugs industry looking to recover from scandals over improper sales practices.
LONDON, Dec 17- GlaxoSmithKline said on Tuesday it would stop paying doctors to promote its products through speaking engagements and end linking compensation for its sales representatives to the number of prescriptions doctors write.
*Executive sees volume growth opportunity in India. With the latest India deal, GSK is set to spend close to $2 billion in roughly a year to increase its holdings in two listed Indian companies, its biggest incremental investment in any country in that period.
Some of Friday's midday movers:
European equities traded lower on Friday, remaining near two-month lows, as investors continued to speculate over Fed tapering.
*AstraZeneca shares gain 2.2 percent. Dec 13- A new type of diabetes drug from Bristol-Myers Squibb and AstraZeneca has been endorsed by U.S. medical experts, two years after it was rejected by regulators because of safety concerns.
Bristol-Myers Squibb is developing the drug, which is already approved in Europe, in partnership with AstraZeneca. The FDA typically follows the advice of its advisory panels, but is under no obligation to do so.
Bristol-Myers is developing the drug, which is already approved in Europe, in partnership with AstraZeneca Plc. The FDA typically follows the advice of its advisory panels, but is under no obligation to do so.
NEW YORK, Dec 3- A U.S. federal judge has awarded AstraZeneca Plc $76 million in damages from generic drug manufacturer Apotex for infringing upon patents for AstraZeneca's blockbuster heartburn drug, Prilosec, between 2003 and 2007..
An "import alert" results in the detention without physical examination of drugs from firms that have not met so-called good manufacturing practices, according to the FDA website.
*Bid at 27 percent premium to Algeta share price at Monday's close. *Algeta shares rise above Bayer offer price in early trade. OSLO/ LONDON, Nov 26- Bayer has offered to pay $2.4 billion for Norway's Algeta, its partner for a new prostate cancer treatment, at a 27 percent premium to the stock's last close, Algeta said on Tuesday.
*Bid at 27 percent premium to Algeta share price at Monday's close. *Algeta shares rise above Bayer offer price in early trade. OSLO/ LONDON, Nov 26- Bayer has offered to pay $2.4 billion for Norway's Algeta, its partner for a new prostrate cancer treatment, a 27 percent premium to the stock's last close, Algeta said on Tuesday.
LONDON, Nov 22- European regulators have recommended approval of a new drug from Gilead Sciences to treat hepatitis C and an HIV medicine from GlaxoSmithKline, both of which are expected to be major sellers.
Dallas, Nov 18- Top cardiologists who devised new U.S. guidelines for reducing risk of heart disease strenuously defended their risk-calculation tool from criticism that it greatly overestimates health risks and the need to be treated with cholesterol lowering statin drugs.
But use of Merck& Co's widely prescribed Zetia, which is not a statin, and Vytorin, a related drug, will likely not be badly hurt anytime soon, analysts said, because doctors will need time to understand and accept the new guidelines. The Merck drugs have combined annual sales of more than $4 billion, or 10 percent of overall company revenue.
Pfizer Inc, Amgen Inc and a partnership of Regeneron Inc and French drugmaker Sanofi SA are racing to develop the new family of medicines called PCSK9 inhibitors. "I read the new guidelines as a negative for any drugs that aren't statins, including PCSK9 inhibitors," said Jon LeCroy, an analyst with MKM Partners.
Focused on high-risk heart attack and stroke patients, the new recommendation are for aggressive drug therapy to lower cholesterol.
LONDON, Nov 11- Cardiologists and shareholders in GlaxoSmithKline are about to learn if a big gamble on a new kind of heart medicine has paid off, with modest expectations creating a potentially big share price boost if the news is good.
LONDON, Oct 31- AstraZeneca is being investigated by U.S. authorities over a major clinical trial that was used to win marketing approval for its new heart drug Brilinta, casting fresh doubts over the medicine. AstraZeneca plans to cooperate with the DOJ and Chief Executive Pascal Soriot said he was "very confident" in the findings of the clinical trial.